Latest News

Dermatology Times debuts a dedicated NP/PA education platform and a new congress series, opening with Derm Nexus this November in Scottsdale, Arizona.

A twice-rejected melanoma immunotherapy finally won accelerated approval, acne's decades-long innovation drought moved a step closer to ending, and 2 rare, sun-triggered skin diseases picked up a deep-pocketed new sponsor.

Week 52 data show ixekizumab plus tirzepatide sustained or improved disease activity and metabolic outcomes in psoriasis and psoriatic arthritis.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Jennifer Soung, MD, discusses whole patient care for psoriasis and alopecia areata and why setting realistic expectations matters for hair regrowth.

Shawn Demehri, MD, PhD, discusses a calcipotriene/5-FU combination immunotherapy for field cancerization and its potential in organ transplant recipients.

Does "flooding" with 5 to 7 products every night really hydrate the skin or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

In this episode, Renata Block, DMSc, MMS, PA-C, welcomed Obehi Oriaifo, DNP, FNP-BC, DCNP, founder of DermaNP Solutions, to discuss expanding teledermatology access for rural and underserved patients.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

Quoin reported positive interim phase 2/3 results for QRX003, which met the primary endpoint in patients with Netherton syndrome.

Paul Rose, MD, JD, discusses nonscalp hair transplantation, patient selection, common misconceptions, and the future of hair restoration.

Learn more about the in-depth topics covered in the August 2026 issue of Dermatology Times.

The FDA approval, based on phase 3 VALOR trial data, makes brepocitinib the first targeted therapy specifically indicated for dermatomyositis.